Lenox Wealth Advisors’s Guardant Health GH Stock Holding History

Lenox Wealth Advisors’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6	Closed	-$1K	–	854
2021 Q4	$1K	Buy	+6	New	+$621	﹤0.01%	841

Other funds holding GH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Lenox Wealth Advisors's GH Position: Q1 2022 in Review

Lenox Wealth Advisors sold out of Guardant Health (GH) in Q1 2022, closing a stake of 6 shares — an estimated $1K sold.

Lenox Wealth Advisors first reported a position in GH in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 355 funds tracked by Wall St. Rank hold GH as of Q1 2022.

Lenox Wealth Advisors reported no remaining Guardant Health position as of Q1 2022 after selling out during the quarter.
Lenox Wealth Advisors sold 6 Guardant Health shares in Q1 2022, an estimated $1K.
Lenox Wealth Advisors first reported a position in Guardant Health in Q4 2021 and held it in 1 quarter.
Lenox Wealth Advisors's Guardant Health position peaked at $1K in Q4 2021.
355 funds tracked by Wall St. Rank held Guardant Health as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.